Syntiron

Better use of vaccines could reduce antibiotic use by 2.5 billion doses annually. #VaccinesWork to reduce the threat of #AntimicrobialResistance by:  ☑️ preventing an infection before it starts  ☑️ reducing the use and overuse of antibiotics  ☑️ slowing the emergence and spread of resistant pathogens    New WHO report finds vaccines could avert deaths, reduce antibiotic doses and save money from treating resistant infections: https://bit.ly/48k06KR  

Thank you to CARB-X product developers, funders, and speakers who convened in Porto, Portugal, on September 16 for the annual CARB-X PD Conference!  More than 100 participants gathered to learn about clinical challenges while working in resource-limited settings, patients’ perspectives, innovation in antibacterial R&D, low- and middle-income country market needs, and more. CARB-X also hosted breakout sessions on #therapeutics, #preventatives, and #diagnostics, giving product developers opportunities to connect with experts in their field.   A special thank you to our speakers Erin Duffy, Usman Nakakana, Leticia de Oliveira Batista, Vanessa Carter, Pernilla Rönnholm, Kevin Outterson, Jong Lee, Alice Troy, Michael Kowarik, Herb Harwell, Trudy Grossman, and Damiano de Felice.    CARB-X remains committed to addressing drug-resistance by hosting events where product developers in the CARB-X Portfolio can connect and share their innovative research and development with stakeholders and the CARB-X team. #AntimicrobialResistance #AMR #SuperBugs #StopSuperBugs #GlobalHealth #Medicine  Boston University Boston University School of Law Biomedical Advanced Research and Development Authority (BARDA) The National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust UK Health Security Agency Department of Health and Social Care Bundesministerium für Bildung und Forschung Bill & Melinda Gates Foundation Novo Nordisk Foundation Government of Canada

Thank you to Chris Dall and Center for Infectious Disease Research and Policy (CIDRAP) for covering this important work! I'm thrilled to have the support of CARB-X and so proud of our team at Syntiron as we evaluate our UTI vaccine for its additional potential to prevent neonatal sepsis when used as a maternal immunization. Let's go!

CARB-X has awarded US$1.7M to Syntiron develop a maternal #vaccine that targets Escherichia coli and Klebsiella pneumoniae, two bacterial species that cause a large proportion of neonatal sepsis infections in babies and urinary tract infections (#UTIs) in mothers. Neonatal sepsis is a life-threatening response to bloodstream infections that occur in newborns fewer than 28 days old. An estimated 2.5 million neonates or infants in the first month of life die annually of sepsis, with the greatest burden in low- and middle-income countries. Syntiron is the third project and second vaccine to receive a CARB-X award as part of the 2022-2023 funding call. Additional projects are under review, and new product developers will be announced this year. 🚨Read more: https://bit.ly/41UlzGJ Register for the CARB-X newsletter to learn more about upcoming funding calls that will be announced in 2024. 🡪 https://lnkd.in/gvizEY32 Syntiron Boston University School of Law Boston University Biomedical Advanced Research and Development Authority (BARDA) HHS Administration for Strategic Preparedness and Response The National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust UK Health Security Agency Department of Health and Social Care Bundesministerium für Bildung und Forschung Bill & Melinda Gates Foundation Government of Canada Novo Nordisk Foundation Centre for Cellular and Molecular Platforms (C-CAMP) FIND German Center for Infection Research Institute For Life Science Entrepreneurship (ILSE)